



- (51) **International Patent Classification:**
A61K 39/085 (2006.01) *A61K 47/48* (2006.01)
- (21) **International Application Number:**
PCT/EP2014/061424
- (22) **International Filing Date:**
3 June 2014 (03.06.2014)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
1310008.6 5 June 2013 (05.06.2013) GB
- (71) **Applicant:** GLAXOSMITHKLINE BIOLOGICALS S.A. [BE/BE]; rue de l'Institut 89, B-1330 Rixensart (BE).
- (72) **Inventors:** BIEMANS, Ralph Leon; GlaxoSmithKline Biologicals s.a., rue de l'Institut 89, B-1330 Rixensart (BE). BOUTRIAU, Dominique; GlaxoSmithKline Biologicals s.a., rue de l'Institut 89, B-1330 Rixensart (BE). DE-NOEL, Philippe; GlaxoSmithKline Biologicals s.a., rue de l'Institut 89, B-1330 Rixensart (BE). DUVIVIER, Pierre; GlaxoSmithKline Biologicals s.a., rue de l'Institut 89, B-1330 Rixensart (BE). GORAJ, Carine; GlaxoSmithKline Biologicals s.a., rue de l'Institut 89, B-1330 Rixensart (BE).
- (74) **Agent:** JOHNSTON, Caroline Louise; GlaxoSmithKline, Global Patents CN925.1, 980 Great West Road, Brentford Middlesex TW8 9GS (GB).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))

(54) **Title:** IMMUNOGENIC COMPOSITION FOR USE IN THERAPY

(57) **Abstract:** The application discloses a method of immunising against Staphylococcus aureus infection comprising a step of administering to a human patient a single dose of an immunogenic composition comprising a Staphylococcus aureus Type 5 capsular saccharide conjugated to a carrier protein to form a S. aureus Type 5 capsular saccharide conjugate, wherein the S. aureus Type 5 capsular saccharide conjugate is administered at a saccharide dose of 3- 50µg.

